Drugs & Aging

, Volume 21, Issue 13, pp 865–883 | Cite as

New Progestogens

A Review of Their Effects in Perimenopausal and Postmenopausal Women
  • Régine Sitruk-Ware
Review Article


The progestins have different pharmacological properties depending upon the parent molecule, usually testosterone or progesterone, from which they are derived. Very small structural changes in the parent molecule may induce considerable differences in the activity of the derivative. In postmenopausal women with an intact uterus, progestins are used in combination with estrogen as hormone-replacement therapy (HRT). The development of new generations of progestins with improved selectivity profiles has been a great challenge. Steroidal and nonsteroidal progesterone-receptor (PR) agonists have been synthesised as well, although the latter are still in a very early stage of development. Several new progestins, which have been synthesised in the last 2 decades, may be considered fourth-generation progestins. These include dienogest, drospirenone, Nestorone® (Population Council, New York, NY, USA), nomegestrol acetate and trimegestone. The fourth-generation progestins have been designed to have no androgenic or estrogenic actions and to be closer in activity to the physiological hormone progesterone. Drospirenone differs from the classic progestins as it is derived from spirolactone. It is essentially an antimineralocorticoid steroid with no androgenic effect but a partial antiandrogenic effect. The antiovulatory potency of the different progestins varies. Trimegestone and Nestorone® are the most potent progestins synthesised to date, followed by two of the older progestins, 3-ketodesogestrel and levonorgestrel. The new molecules trimegestone, drospirenone and dienogest also have antiandrogenic activity.

Following the publication of the results of the Women’s Health Initiative study, the role of progestins in HRT became controversial. Unfortunately, this concern has been directed towards progestins as a class, although striking differences exist among the progestins. Natural progesterone and some of its derivatives, such as the 19-norprogesterone molecules, and the new molecules drospirenone and dienogest are not androgenic and, therefore, have no negative effect on the lipid profile. The effects of progestins on breast tissue remain controversial as well. However, depending on the progestin and the duration of application, breast cell differentiation and apoptosis may predominate over proliferation. It is still unclear if the currently available progestins are able to bind specifically to the PR isoforms PR-A or PR-B and whether this is of clinical relevance to breast cell proliferation is also unclear. Although it is likely that the new progestins may have neutral effects on the risk of coronary heart disease or breast cancer in younger postmenopausal women, this hypothesis must be confirmed in large randomised, well controlled clinical trials.


Androgen Receptor Progestin Mineralocorticoid Receptor Levonorgestrel Medroxyprogesterone Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this manuscript. The author thanks Barbara Tokay for editorial assistance. Nestorone® (Population Council, New York, NY, USA), a progestin mentioned in this review, was developed by the Population Council; development of Nestorone® for contraceptive use was funded by grants from the United States Agency for International Development and the National Institute of Child Health and Development. The views of the author do not necessarily reflect those of the Population Council or the funding agencies.

The author has no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003 Mar–Apr; 10(2): 113–32CrossRefGoogle Scholar
  2. 2.
    Sitruk-Ware R. Therapeutic uses of progestins: practical recommendations. In: Sitruk-Ware R, Mishell Jr DR, editors. Progestins and antiprogestins in clinical practice. New York: M Dekker, 2000: 341–53Google Scholar
  3. 3.
    Sturdee DW, Barlow DH, Ulrich LG, et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogens/progestagen replacement therapy? UK continuous combined HRT study investigators. Lancet 1994 Oct 8; 344(8928): 979–82PubMedCrossRefGoogle Scholar
  4. 4.
    Gambrell RD, Massey FM, Castaneda TA, et al. The use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980; 55(6): 732–8PubMedGoogle Scholar
  5. 5.
    Sitruk-Ware R. Progestins in hormonal replacement therapy and prevention of endometrial disease. In: Sitruk-Ware R, Mishell Jr DR, editors. Progestins and antiprogestins in clinical practice. New York: M Dekker, 2000: 269–77Google Scholar
  6. 6.
    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288(3): 321–33CrossRefGoogle Scholar
  7. 7.
    Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283(4): 485–91PubMedCrossRefGoogle Scholar
  8. 8.
    Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003 Aug 9; 362(9382): 419–27PubMedCrossRefGoogle Scholar
  9. 9.
    Magnusson C, Baron JA, Correira N, et al. Breast cancer risk following long term oestrogen- and oestrogen-progestin replacement therapy. Int J Cancer 1999 May 5; 81(3): 339–44PubMedCrossRefGoogle Scholar
  10. 10.
    Henzl MR, Edwards JA. Pharmacology of progestins: 17α-hydroxyprogesterone derivatives and progestins of the first and second generation. In: Sitruk-Ware R, Mishell Jr DR, editors. Progestins and antiprogestins in clinical practice. New York: M Dekker, 2000: 101–32Google Scholar
  11. 11.
    Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord 2002 Sep; 3(3): 211–24PubMedCrossRefGoogle Scholar
  12. 12.
    Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002; 9(1): 6–15PubMedCrossRefGoogle Scholar
  13. 13.
    Liu Z, Auboeuf D, Wong J, et al. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci U S A 2002 Jun 11; 99(12): 7940–4PubMedCrossRefGoogle Scholar
  14. 14.
    Wright F, Giacomini M, Riahi M, et al. Antihormone activity of progesterone and progestins. In: Bardin CW, Milgroom E, Mauvais-Jarvis P, editors. Progesterone and progestins. New York: Raven Press Books, 1983: 121–34Google Scholar
  15. 15.
    Corvol P, Elkik F, Feneant M, et al. Effect of progesterone and progestins on water and salt metabolism. In: Bardin CW, Milgröm E, Mauvais-Jarvis P, editors. Progesterone and progestins. New York: Raven Press Books, 1983: 179–86Google Scholar
  16. 16.
    Oettel M, Holz C. Hybrid progestins: the example of dienogest. In: Sitruk-Ware R, Mishell Jr DR, editors. Progestins and antiprogestins in clinical practice. New York: M Dekker, 2000: 163–78Google Scholar
  17. 17.
    Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995 Jun; 80(6): 1816–21PubMedCrossRefGoogle Scholar
  18. 18.
    Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996 Feb; 51(2): 188–215PubMedCrossRefGoogle Scholar
  19. 19.
    Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003; 46S1: S7–S16CrossRefGoogle Scholar
  20. 20.
    Kumar N, Koide SS, Tsong YY, et al. Nestorone®: a progestin with a unique pharmacological profile. Steroids 2000; 65: 629–36PubMedCrossRefGoogle Scholar
  21. 21.
    Tuba Z, Bardin CW, Dancsi A, et al. Synthesis and biological activity of a new progestogen, 16-methylene-17α-hydrox-y-18-methyl-10-norpregn-4-ene-3,20-dione acetate. Steroids 2000; 65: 266–74PubMedCrossRefGoogle Scholar
  22. 22.
    Duc I, Botella J, Bonnet P, et al. Antiandrogenic properties of nomegestrol acetate. Arzneimittel Forschung 1995 Jan; 45(1): 70–4PubMedGoogle Scholar
  23. 23.
    Philibert D, Bouchoux F, Degryse M, et al. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999 Oct; 13(5): 316–26PubMedCrossRefGoogle Scholar
  24. 24.
    Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000 Jul; 62(1): 29–38PubMedCrossRefGoogle Scholar
  25. 25.
    Giangrande PH, McDonnell DP. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 1999; 54: 291–313PubMedGoogle Scholar
  26. 26.
    Zimmermann H, Thebault JJ, Durauchelle T, et al. Pharmacokinetics of estradiol valerate 2mg + dienogest 2mg (Climodien® 2/2) after single and repeated oral administration in healthy postmenopausal women. Clin Drug Invest 2000; 20: 123–34CrossRefGoogle Scholar
  27. 27.
    Teichmann A. Pharmacology of estradiol valerate/dienogest. Climacteric 2003; 6Suppl. 2: 17–23PubMedGoogle Scholar
  28. 28.
    Wiegratz I, Lee JH, Kutschera E, et al. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception 2002; 65(3): 223–9PubMedCrossRefGoogle Scholar
  29. 29.
    Foster RH, Wilde MI. Dienogest. Drugs 1998; 56(5): 825–33PubMedCrossRefGoogle Scholar
  30. 30.
    Gräser T, Koytchev R. Müller A, et al. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women. Climacteric 2000 Jun; 3(2): 109–18PubMedCrossRefGoogle Scholar
  31. 31.
    Mueck AO, Seeger H, Ludtke R, et al. Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: estradiol versus estradiol/dienogest. Maturitas 2001; 38(3): 305–13PubMedCrossRefGoogle Scholar
  32. 32.
    Anderer P, Semlitsch HV, Saletu B, et al. Effects of hormone replacement therapy on perceptual and cognitive event-related potentials in menopausal insomnia. Psychoneuroendocrinology 2003 Apr; 28(3): 419–45PubMedCrossRefGoogle Scholar
  33. 33.
    Saletu B, Brandstatter N, Metka M, et al. Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls. Maturitas 1996; 23(1): 91–105PubMedCrossRefGoogle Scholar
  34. 34.
    Saletu B, Anderer P, Gruber D, et al. Hormone replacement therapy and vigilance double-blind, placebo-controlled EEG-mapping studies with an estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone in menopausal syndrome patients. Maturitas 2002 Nov 20; 43(3): 165–81PubMedCrossRefGoogle Scholar
  35. 35.
    Smith YR, Giordani B, Lajiness-O’Neil R, et al. Long-term estrogen replacement is associated with improved nonverbal memory and attentional measures in postmenopausal women. Fertil Steril 2001; 76(6): 1101–7PubMedCrossRefGoogle Scholar
  36. 36.
    Carlson MC, Zandi PP, Plassman BL, et al. Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study. Neurology 2001; 57(12): 2210–6PubMedCrossRefGoogle Scholar
  37. 37.
    Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289(20): 2651–62PubMedCrossRefGoogle Scholar
  38. 38.
    Elger W, Beier S, Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids 2003; 68(10–13): 891–905PubMedCrossRefGoogle Scholar
  39. 39.
    Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54(4): 243–51PubMedCrossRefGoogle Scholar
  40. 40.
    Pollow K, Juchem M, Elger W, et al. Dihydrospirorenone (ZK30595): a novel synthetic progestagen: characterization of binding to different receptor proteins. Contraception 1992; 46(6): 561–74PubMedCrossRefGoogle Scholar
  41. 41.
    Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the rennin-aldosterone system in normal women. J Clin Endocrinol Metab 1991 Oct; 73(4): 837–42PubMedCrossRefGoogle Scholar
  42. 42.
    Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric 2003; 6Suppl. 3: 49–54PubMedGoogle Scholar
  43. 43.
    Preston RA, Alonso A, Panzitta D, et al. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002; 15(9): 816–22PubMedCrossRefGoogle Scholar
  44. 44.
    Zhang Z, Lundeen SG, Zhu Y, et al. In vitro characterization of trimegestone: a new potent and selective progestin. Steroids 2000; 65(10–13): 637–43PubMedCrossRefGoogle Scholar
  45. 45.
    Paris J, Thevenot R, Bonnet P, et al. The pharmacological profile of TX 066 (17alpha-acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione) a new oral progestative. Arzneimittel Forschung 1983; 33(5): 710–5PubMedGoogle Scholar
  46. 46.
    Lundeen SB, Zhang Z, Zhu Y, et al. Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone. J Steroid Biochem Mol Biol 2001; 78(2): 137–43PubMedCrossRefGoogle Scholar
  47. 47.
    Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 2003; 68(10–13): 915–20PubMedCrossRefGoogle Scholar
  48. 48.
    Bouali Y, Gaillard-Kelly M, Marie PJ. Effect of trimegestone alone or in combination with estradiol on bone mass and bone turnover in an adult rat model of osteopenia. Gynecol Endocrinol 2001; 15(1): 48–55PubMedCrossRefGoogle Scholar
  49. 49.
    Gaspard U. 17 beta-estradiol/trimegestone: expanding low dose HT options with trimegestone [abstract]. Symposium on the New Direction in HRT. XVII FIGO World Congress of Gynecology and Obstetrics; 2003 Nov 2–7; SantiagoGoogle Scholar
  50. 50.
    Al Azzawi F, Wahab M, Thompson J, et al. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric 2001; 4(4): 343–54PubMedGoogle Scholar
  51. 51.
    Wahab M, Al Azzawi F. Trimegestone: expanding therapeutic choices for the treatment of the menopause. Expert Opin Investig Drugs 2001; 10(9): 1737–44PubMedCrossRefGoogle Scholar
  52. 52.
    Meuwissen JH, Beijers-De Bie L, Vihtamaki T, et al. Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone. Gynecol Endocrinol 2002; 16(2): 155–62PubMedGoogle Scholar
  53. 53.
    Sitruk-Ware R, Small M, Kumar N, et al. Nestorone®: clinical applications for contraception and HRT. Steroids 2003; 68(10–13): 907–13PubMedCrossRefGoogle Scholar
  54. 54.
    Fotherby K. Potency and pharmacokinetics of gestagens. Contraception 1990; 41(5): 533–50PubMedCrossRefGoogle Scholar
  55. 55.
    Noe G, Salvatierra A, Heikinheimo O, et al. Pharmacokinetics and bioavailability of ST 1435 administered by different routes. Contraception 1993; 48(6): 548–56PubMedCrossRefGoogle Scholar
  56. 56.
    Oettel M, Graser T, Hoffman H. Why dienogest as a progestogenic component of postmenopausal nonandrogenic hormone replacement therapy? Drugs Today 2001; 37Suppl. G: 3–15Google Scholar
  57. 57.
    Hellman L, Yoshida K, Zumoff B, et al. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab 1976; 42(5): 912–7PubMedCrossRefGoogle Scholar
  58. 58.
    Guthrie GP, John WJ. The in vivo glucocorticoid and antiglucocorticoid actions of medroxyprogesterone acetate. Endocrinology 1980 Nov; 107(5): 1393–6PubMedCrossRefGoogle Scholar
  59. 59.
    Brache V, Mishell DR, Lahteenmaki P, et al. Ovarian function during use of vaginal rings delivering three different doses of Nestorone. Contraception 2001; 63(5): 257–61PubMedCrossRefGoogle Scholar
  60. 60.
    Sitruk-Ware R, Small M. New methods of progestin delivery. Contemp Clin Gynecol Obstet 2002; 2: 287–98Google Scholar
  61. 61.
    Kumar S, Menard J, Kumar N, et al. Antiestrogenic effects of Nestorone as compared to other progestins [abstract no. P3-14]. 85th Annual Endocrine Society Meeting; 2003 Jun 19–22; Philadelphia, 478Google Scholar
  62. 62.
    Bullock LP, Bardin CW. Androgenic, synandrogenic, and antiandrogenic actions of progestins. Ann N Y Acad Sci 1977; 286: 321–30PubMedCrossRefGoogle Scholar
  63. 63.
    Dusterberg B, Humpel M, Speck U. Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys. Contraception 1981; 24(6): 673–83PubMedCrossRefGoogle Scholar
  64. 64.
    Conard J, Basdevant A, Thomas JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 1995 Nov; 64(5): 957–62PubMedGoogle Scholar
  65. 65.
    Couzinet B, Young J, Brailly S, et al. The antigonadotropic activity of progestins (19-nortestosterone and 19-norprogester-one derivatives) is not mediated through the androgen receptor. J Clin Endocrinol Metab 1996 Dec; 81(12): 4218–23PubMedCrossRefGoogle Scholar
  66. 66.
    Bazin B, Thevenot R, Bursaux C, et al. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br J Obstet Gynaecol 1987 Dec; 94(12): 1199–204PubMedCrossRefGoogle Scholar
  67. 67.
    Coutinho EM. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant). Contraception 1993 Jan; 47(1): 97–105PubMedCrossRefGoogle Scholar
  68. 68.
    Devoto L, Kohen P, Barnhart K, et al. Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant). Hum Reprod 1997 Apr; 12(4): 708–13PubMedCrossRefGoogle Scholar
  69. 69.
    Williams JK, Honore EK, Washburn SA, et al. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994; 24(7): 1757–61PubMedCrossRefGoogle Scholar
  70. 70.
    Williams JK, Cline JM, Honore EK, et al. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in nonhuman primates (Macaca fascicularis). Am J Obstet Gynecol 1998; 179(5): 1288–94PubMedCrossRefGoogle Scholar
  71. 71.
    Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990; 10(6): 1051–7PubMedCrossRefGoogle Scholar
  72. 72.
    Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003 Aug 7; 349(6): 523–34PubMedCrossRefGoogle Scholar
  73. 73.
    Akhrass F, Evans AT, Wang Y, et al. Hormone replacement therapy is associated with less coronary atherosclerosis. J Clin Endocrinol Metab 2003; 88: 5611–4PubMedCrossRefGoogle Scholar
  74. 74.
    Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982; 2(1): 5–73PubMedCrossRefGoogle Scholar
  75. 75.
    Conneely OM, Lydon JP. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 2000; 65(10–11): 571–7PubMedCrossRefGoogle Scholar
  76. 76.
    Kenemans P, Bosman A. Breast cancer and post-menopausal hormone therapy. Best Pract Res Clin Endocrinol Metab 2003; 17(1): 123–37PubMedCrossRefGoogle Scholar
  77. 77.
    Isaksson E, Wang H, Sahlin L, et al. Effects of long-term HRT and tamoxifen on the expression of progesterone receptors A and B in breast tissue from surgically postmenopausal cynomolgus macaques. Breast Cancer Res Treat 2003; 79(2): 233–9PubMedCrossRefGoogle Scholar
  78. 78.
    Thijssen JH. Oestrogens, progestins and breast proliferation. Zentralbl Gynakol 1997; 119Suppl. 2: 43–7PubMedGoogle Scholar
  79. 79.
    Gompel A, Somai S, Chaouat M, et al. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 2000; 65(10–11): 593–8PubMedCrossRefGoogle Scholar
  80. 80.
    Desreux J, Kebers F, Noel A, et al. Effects of a progestogen on normal human breast epithelial cell apoptosis in vitro and in vivo. Breast 2003; 12(2): 142–9PubMedCrossRefGoogle Scholar
  81. 81.
    Musgrove EA, Lee CS, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 1991; 11(10): 5032–43PubMedGoogle Scholar
  82. 82.
    Alkhalaf M, El Mowafy A, Karam S. Growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with cell differentiation and phosphorylation of Akt protein. Eur J Cancer Prev 2002; 11(5): 481–8PubMedCrossRefGoogle Scholar
  83. 83.
    Cline JM, Soderqvist G, von Schoultz E, et al. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996; 174 (1 Pt 1): 93–100PubMedCrossRefGoogle Scholar
  84. 84.
    Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999; 84(12): 4559–65PubMedCrossRefGoogle Scholar
  85. 85.
    Suparto IH, Williams JK, Cline JM, et al. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys. Am J Obstet Gynecol 2003; 188(5): 1132–40PubMedCrossRefGoogle Scholar
  86. 86.
    Conner P, Soderqvist G, Skoog L, et al. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 2003; 78(2): 159–65PubMedCrossRefGoogle Scholar
  87. 87.
    Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993; 67(5): 945–52PubMedCrossRefGoogle Scholar
  88. 88.
    Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995; 55(2): 239–46PubMedCrossRefGoogle Scholar
  89. 89.
    Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350(9084): 1047–59Google Scholar
  90. 90.
    Speroff L. The Million Women Study and breast cancer. Maturitas 2003; 46(1): 1–6PubMedCrossRefGoogle Scholar
  91. 91.
    Greendale GA, Reboussin BA, Slone S, et al. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003 Jan 1; 95(1): 30–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Rockefeller University and Population CouncilNew YorkUSA

Personalised recommendations